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Location of Thrombus in
Atrial Fibrillation
We read with great interest the imaging vignette by Gurudevan et
al. (1), presenting 3 patients in whom a thrombus was seen adherent
to the septal left atrium (LA), potentially attributed to a recently
described novel atrial structure, the left atrial septal pouch (LASP).
Krishnan et al. (2) described this new structure and concluded that
LASP has the potential to be a site of stasis with thromboembolic
complications, although Tugcu et al. (3) did not demonstrate
evidence of the association of the presence of LASP with ischemic
stroke or cryptogenic stroke. From these conflicting results, we have
2 comments regarding the underlying pathophysiology and the
clinical implication of LASP.
First, it is really important, in our view, to investigate the effect of
LASP on thromboembolic complications in patients with underlying
cardiovascular disease causing alterations in blood flow. Especially in
patients with rheumatic mitral valve stenosis, with or without atrial
fibrillation, the location of thrombus formation in the left atrium appears
to be different compared to other prothrombotic disease states. In the
presence of atrial fibrillation and rheumatic mitral valve stenosis, in 50%
of the cases, the thrombus is not located in the left atrial appendage
versus 90% of the thrombi found in the appendage in nonvalvular atrial
fibrillation (1).
Second, in patients with mitral valve stenosis, LASP might
potentially be even more prothrombotic, considering: 1) the loca-
tion of thrombus; and 2) the increased risk for atrial fibrillation. This
hypothesis is supported by the increased incidence of thromboembolism
that occurs during transseptal valvuloplasty of the mitral stenosis,
varying from 0.48% to 3.0% (4), compared to the absence of cerebro-
vascular events in case of retrograde mitral valvuloplasty, where there is
no interference with the atrial septum (5). Therefore, the role of LASP in
ischemic stroke or cryptogenic stroke in patients undergoing transseptal
mitral valvuloplasty might be important. On the contrary, retrograde
mitral balloon valvuloplasty in patients with LASP may reduce the
thromboembolic complications. Thus, in patients with mitral valve steno-
sis, the selection of the technique for the optimal outcome might depend
also on the presence of LASP. dThese considerations need to be further investigated. The
mmediate clinical implications after the current observations include the
nvestigation of the presence ofLASP in specific groups, such as rheumatic
itral valve stenosis, because LASP might be an additional criterion for
he choice of treatment. A prospective study is justified with echocardio-
raphic and clinical end points to investigate the accurate prognostic role of
ASP in stroke.
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REPLY
We greatly appreciate the comments and suggestions by Drs.
Toutouzas and colleagues (1) regarding our recent paper on the left
atrial septal pouch (LASP) and thromboembolism (2).
We are pleased that they agree with our proposed mechanism on the
conditions where the LASP is potentially thrombogenic, that is, presence
of sluggish flow of blood arising from the right pulmonary veins (RPV).
According to this hypothesis, RPV blood that flows adjacent to the LASP
in a brisk and laminar fashion plays a protective antithrombotic role
(Figure 5 of our article [2]). Loss of this protective mechanism would be
expected in heart failure or in mitral stenosis (MS) with consequent
thrombogenesis. Our hypothesis may partially explain the increased
incidence of thrombi seen outside the left atrial appendage in rheu-
matic MS. Similarly, sluggish blood flow from the RPV may also play a
role in thrombus formation on septal closure devices, especially with
suboptimally seated devices (creating an “iatrogenic” LASP) (3).We agree
that a prospective study is justified to investigate the thromboembolic
potential of LASP in various disease conditions.
The authors also propose that in patients with MS undergoing
percutaneous valvuloplasty, a retrograde transaortic approach may be
safer than a transseptal approach. They quote a 0.48% to 3.0% incidence
of thromboembolism that occurs during transseptal valvuloplasty
compared to the absence of strokes with a transaortic approach (4,5).
hey raise the intriguing possibility that some of the strokes seen with
he transatrial valvuloplasty approach may have been due to the
islodgment of a thrombus adherent to a LASP. However, in the
